Targeted delivery of nanoparticles for in vivo CAR T therapy

Strike Pharma is a Swedish biotech company developing in vivo CAR-T therapies for autoimmune disease and cancer based on a proprietary technology for targeted LNP delivery

Learn more about our technology, pipeline and disease indications, and see our publications and posters.

Latest News

News

February 4, 2025

Per Norlén joins Strike Pharma as new CEO

News

September 10, 2024

Strike Pharma presents updates at CICON24

News

July 4, 2024

Strike Pharma granted patent to protect core technology

News

July 4, 2024

Strike Pharma receives funding from BIO-X Accelerate program

Event

September 24, 2023

Strike Pharma presents further developments at CICON23

News

May 16, 2023

Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate

Event

April 18, 2023

Strike Pharma presents latest developments at AACR 2023

News

December 5, 2022

Funds awarded to study ADAC™ technology in depth

News

November 3, 2022

Strike Pharma continues expansion of management team

News

October 20, 2022

Strike Pharma and FyoniBio sign Master Service Agreement

News

August 30, 2022

Strike Pharma’s Chief Scientific Officer receives BiotechBuilders Award 2022

News

June 20, 2022

Strike Pharma strengthens Board of Directors

See more News

Latest Events

See more Events